JP2012508752A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012508752A5 JP2012508752A5 JP2011536447A JP2011536447A JP2012508752A5 JP 2012508752 A5 JP2012508752 A5 JP 2012508752A5 JP 2011536447 A JP2011536447 A JP 2011536447A JP 2011536447 A JP2011536447 A JP 2011536447A JP 2012508752 A5 JP2012508752 A5 JP 2012508752A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- hydroxy
- amino
- carbonyl
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 106
- 239000001257 hydrogen Substances 0.000 claims description 106
- 150000001875 compounds Chemical class 0.000 claims description 76
- 125000000217 alkyl group Chemical group 0.000 claims description 74
- 125000001072 heteroaryl group Chemical group 0.000 claims description 71
- 150000002431 hydrogen Chemical class 0.000 claims description 60
- 125000003118 aryl group Chemical group 0.000 claims description 58
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 46
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 46
- 125000003107 substituted aryl group Chemical group 0.000 claims description 38
- 125000005843 halogen group Chemical group 0.000 claims description 32
- 125000003545 alkoxy group Chemical group 0.000 claims description 31
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 22
- 125000004442 acylamino group Chemical group 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 20
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 20
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 20
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 19
- 108010074633 Mixed Function Oxygenases Proteins 0.000 claims description 18
- 102000008109 Mixed Function Oxygenases Human genes 0.000 claims description 18
- -1 amino, substituted amino Chemical group 0.000 claims description 15
- 125000004414 alkyl thio group Chemical group 0.000 claims description 12
- 125000005110 aryl thio group Chemical group 0.000 claims description 12
- 125000004104 aryloxy group Chemical group 0.000 claims description 12
- 125000005366 cycloalkylthio group Chemical group 0.000 claims description 12
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 12
- 125000005368 heteroarylthio group Chemical group 0.000 claims description 12
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 150000001768 cations Chemical class 0.000 claims description 9
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 8
- 229910052805 deuterium Inorganic materials 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 8
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 208000028867 ischemia Diseases 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 229940002612 prodrug Drugs 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000005338 substituted cycloalkoxy group Chemical group 0.000 claims description 6
- 108010043005 Prolyl Hydroxylases Proteins 0.000 claims description 5
- 102000004079 Prolyl Hydroxylases Human genes 0.000 claims description 5
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 102000003951 Erythropoietin Human genes 0.000 claims description 4
- 108090000394 Erythropoietin Proteins 0.000 claims description 4
- 206010021143 Hypoxia Diseases 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 239000003173 antianemic agent Substances 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 229940125367 erythropoiesis stimulating agent Drugs 0.000 claims description 4
- 229940105423 erythropoietin Drugs 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 4
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 4
- 101000881648 Homo sapiens Egl nine homolog 1 Proteins 0.000 claims description 3
- 101000881650 Homo sapiens Prolyl hydroxylase EGLN2 Proteins 0.000 claims description 3
- 101000881678 Homo sapiens Prolyl hydroxylase EGLN3 Proteins 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 102000053692 human EGLN1 Human genes 0.000 claims description 3
- 102000048660 human EGLN2 Human genes 0.000 claims description 3
- 102000050122 human EGLN3 Human genes 0.000 claims description 3
- 230000007954 hypoxia Effects 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 claims description 2
- IXIOECWKRVUDLF-UHFFFAOYSA-N BrC1=CC=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=C1 Chemical compound BrC1=CC=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=C1 IXIOECWKRVUDLF-UHFFFAOYSA-N 0.000 claims description 2
- WQTCYWYJKJQSAM-YFKPBYRVSA-N BrC1=CC=C2SC(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1 Chemical compound BrC1=CC=C2SC(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1 WQTCYWYJKJQSAM-YFKPBYRVSA-N 0.000 claims description 2
- GJTJYXZBBIZYJK-UHFFFAOYSA-N C1=C(Br)C=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=C1 Chemical compound C1=C(Br)C=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=C1 GJTJYXZBBIZYJK-UHFFFAOYSA-N 0.000 claims description 2
- FEYNWGLOBSTRAA-UHFFFAOYSA-N C1=C(Cl)C=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=C1 Chemical compound C1=C(Cl)C=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=C1 FEYNWGLOBSTRAA-UHFFFAOYSA-N 0.000 claims description 2
- KBXAMUNIGUTQJG-YFKPBYRVSA-N C1=C(Cl)C=C2SC(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1 Chemical compound C1=C(Cl)C=C2SC(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1 KBXAMUNIGUTQJG-YFKPBYRVSA-N 0.000 claims description 2
- AZDCEPBCDALDSS-UHFFFAOYSA-N C1=C(F)C=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=C1 Chemical compound C1=C(F)C=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=C1 AZDCEPBCDALDSS-UHFFFAOYSA-N 0.000 claims description 2
- JBUNXCKXWVRXSX-UHFFFAOYSA-N C1=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=C1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 Chemical compound C1=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=C1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 JBUNXCKXWVRXSX-UHFFFAOYSA-N 0.000 claims description 2
- OLJXCCNBPKGQAR-UHFFFAOYSA-N C1=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=C1C1=CC(Cl)=CC(Cl)=C1 Chemical compound C1=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=C1C1=CC(Cl)=CC(Cl)=C1 OLJXCCNBPKGQAR-UHFFFAOYSA-N 0.000 claims description 2
- PBPXOKWYULFMPG-UHFFFAOYSA-N C1=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=C1C1=CC=C(C(F)(F)F)C=C1 Chemical compound C1=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=C1C1=CC=C(C(F)(F)F)C=C1 PBPXOKWYULFMPG-UHFFFAOYSA-N 0.000 claims description 2
- HGWXWNWWGHPMMD-UHFFFAOYSA-N C1=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=C1C1=CC=C(F)C(Cl)=C1 Chemical compound C1=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=C1C1=CC=C(F)C(Cl)=C1 HGWXWNWWGHPMMD-UHFFFAOYSA-N 0.000 claims description 2
- ASFJVZHJBQQQJC-UHFFFAOYSA-N C1=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=C1C1=CC=CC(F)=C1 Chemical compound C1=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=C1C1=CC=CC(F)=C1 ASFJVZHJBQQQJC-UHFFFAOYSA-N 0.000 claims description 2
- WWJFXWAPFPLBCN-UHFFFAOYSA-N C1=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=C1C1=CC=CC=C1 Chemical compound C1=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=C1C1=CC=CC=C1 WWJFXWAPFPLBCN-UHFFFAOYSA-N 0.000 claims description 2
- NUVPQXNGBSTYLE-UHFFFAOYSA-N C1=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=C1C1=CC=CC=C1C(F)(F)F Chemical compound C1=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=C1C1=CC=CC=C1C(F)(F)F NUVPQXNGBSTYLE-UHFFFAOYSA-N 0.000 claims description 2
- OPIRGLLSCYBQNL-UHFFFAOYSA-N C1=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=C1C1=CN=CC(F)=C1 Chemical compound C1=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=C1C1=CN=CC(F)=C1 OPIRGLLSCYBQNL-UHFFFAOYSA-N 0.000 claims description 2
- VZHYIGUYSZMGKP-UHFFFAOYSA-N C1=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=C1C1=CN=CN=C1 Chemical compound C1=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=C1C1=CN=CN=C1 VZHYIGUYSZMGKP-UHFFFAOYSA-N 0.000 claims description 2
- GCIDWUXOAZVSCZ-UHFFFAOYSA-N C1=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=C1C1CC1 Chemical compound C1=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=C1C1CC1 GCIDWUXOAZVSCZ-UHFFFAOYSA-N 0.000 claims description 2
- LFPRUGYROLOMOH-UHFFFAOYSA-N C1=CC(C)=CC=C1C1=CC=C(C(O)=C(C(=O)NCC(O)=O)C(=O)S2)C2=C1 Chemical compound C1=CC(C)=CC=C1C1=CC=C(C(O)=C(C(=O)NCC(O)=O)C(=O)S2)C2=C1 LFPRUGYROLOMOH-UHFFFAOYSA-N 0.000 claims description 2
- MDUBXNWENMYSAP-UHFFFAOYSA-N C1=CC(OC)=CC=C1C1=CC=C(SC(=O)C(C(=O)NCC(O)=O)=C2O)C2=C1 Chemical compound C1=CC(OC)=CC=C1C1=CC=C(SC(=O)C(C(=O)NCC(O)=O)=C2O)C2=C1 MDUBXNWENMYSAP-UHFFFAOYSA-N 0.000 claims description 2
- OBYIWXRCSLJMJA-UHFFFAOYSA-N C1=CC=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=C1 Chemical compound C1=CC=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=C1 OBYIWXRCSLJMJA-UHFFFAOYSA-N 0.000 claims description 2
- SWZYAYLGHJBFDI-LURJTMIESA-N C1=CC=C2SC(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1 Chemical compound C1=CC=C2SC(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1 SWZYAYLGHJBFDI-LURJTMIESA-N 0.000 claims description 2
- HGNVYEFOAOEMFU-UHFFFAOYSA-N C1=CC=CC2=CC(C3=CC=C4C(O)=C(C(SC4=C3)=O)C(=O)NCC(=O)O)=CC=C21 Chemical compound C1=CC=CC2=CC(C3=CC=C4C(O)=C(C(SC4=C3)=O)C(=O)NCC(=O)O)=CC=C21 HGNVYEFOAOEMFU-UHFFFAOYSA-N 0.000 claims description 2
- CLFTZRBJHZWJEP-UHFFFAOYSA-N C=12SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC(Cl)=CC=1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 Chemical compound C=12SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC(Cl)=CC=1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CLFTZRBJHZWJEP-UHFFFAOYSA-N 0.000 claims description 2
- XUFIIIBKCZOYSW-UHFFFAOYSA-N C=12SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC(Cl)=CC=1C1=CC=CC=C1 Chemical compound C=12SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC(Cl)=CC=1C1=CC=CC=C1 XUFIIIBKCZOYSW-UHFFFAOYSA-N 0.000 claims description 2
- RNKJKCXSTJDHBB-UHFFFAOYSA-N C=12SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC(Cl)=CC=1C1=CC=CN=C1 Chemical compound C=12SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC(Cl)=CC=1C1=CC=CN=C1 RNKJKCXSTJDHBB-UHFFFAOYSA-N 0.000 claims description 2
- IHZKLVVXBJKQMN-UHFFFAOYSA-N C=12SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=CC=1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 Chemical compound C=12SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=CC=1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 IHZKLVVXBJKQMN-UHFFFAOYSA-N 0.000 claims description 2
- YQNYCTVBUVEQKV-UHFFFAOYSA-N C=12SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=CC=1C1=CC=CC=C1 Chemical compound C=12SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=CC=1C1=CC=CC=C1 YQNYCTVBUVEQKV-UHFFFAOYSA-N 0.000 claims description 2
- RBWLNGNEAPNXBJ-UHFFFAOYSA-N C=12SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=CC=1C1=CC=CN=C1 Chemical compound C=12SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=CC=1C1=CC=CN=C1 RBWLNGNEAPNXBJ-UHFFFAOYSA-N 0.000 claims description 2
- INYXVNNBOHSTQI-UHFFFAOYSA-N C=12SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=CC=1CC1=CC=CC=C1 Chemical compound C=12SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=CC=1CC1=CC=CC=C1 INYXVNNBOHSTQI-UHFFFAOYSA-N 0.000 claims description 2
- BCSSPVDVTWJFNE-UHFFFAOYSA-N C=1C=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 Chemical compound C=1C=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 BCSSPVDVTWJFNE-UHFFFAOYSA-N 0.000 claims description 2
- YQCJZNKYBVAGOU-UHFFFAOYSA-N C=1C=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=1C1=CC=C(F)C=C1 Chemical compound C=1C=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=1C1=CC=C(F)C=C1 YQCJZNKYBVAGOU-UHFFFAOYSA-N 0.000 claims description 2
- RCVTZPSPGHVSMT-UHFFFAOYSA-N C=1C=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=1C1=CC=CC(F)=C1 Chemical compound C=1C=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=1C1=CC=CC(F)=C1 RCVTZPSPGHVSMT-UHFFFAOYSA-N 0.000 claims description 2
- JEBYKOKTQBKUIO-UHFFFAOYSA-N C=1C=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=1C1=CC=CC=C1C(F)(F)F Chemical compound C=1C=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=1C1=CC=CC=C1C(F)(F)F JEBYKOKTQBKUIO-UHFFFAOYSA-N 0.000 claims description 2
- NPSLYAJXNNGMMO-UHFFFAOYSA-N C=1C=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=1C1=CC=CC=C1Cl Chemical compound C=1C=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=1C1=CC=CC=C1Cl NPSLYAJXNNGMMO-UHFFFAOYSA-N 0.000 claims description 2
- RFWUDQSUZMCGJW-UHFFFAOYSA-N C=1C=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=1NC(=O)C1=CC=CC=C1 Chemical compound C=1C=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=1NC(=O)C1=CC=CC=C1 RFWUDQSUZMCGJW-UHFFFAOYSA-N 0.000 claims description 2
- WIPLMKJUBITHIT-UHFFFAOYSA-N C=1C=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=1OCC1CCCCC1 Chemical compound C=1C=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=1OCC1CCCCC1 WIPLMKJUBITHIT-UHFFFAOYSA-N 0.000 claims description 2
- NNYZPEIIZQQQGF-UHFFFAOYSA-N CN1N=C(C(F)(F)F)C=C1C1=CC=C(C(O)=C(C(=O)NCC(O)=O)C(=O)S2)C2=C1 Chemical compound CN1N=C(C(F)(F)F)C=C1C1=CC=C(C(O)=C(C(=O)NCC(O)=O)C(=O)S2)C2=C1 NNYZPEIIZQQQGF-UHFFFAOYSA-N 0.000 claims description 2
- KGPWUHOVKRHMNK-UHFFFAOYSA-N COC1=CC=CC(C=2C=C3SC(=O)C(C(=O)NCC(O)=O)=C(O)C3=CC=2)=C1 Chemical compound COC1=CC=CC(C=2C=C3SC(=O)C(C(=O)NCC(O)=O)=C(O)C3=CC=2)=C1 KGPWUHOVKRHMNK-UHFFFAOYSA-N 0.000 claims description 2
- QJFIWHWKGQQVNK-UHFFFAOYSA-N COC1=CC=CC=C1C1=CC=C(C(O)=C(C(=O)NCC(O)=O)C(=O)S2)C2=C1 Chemical compound COC1=CC=CC=C1C1=CC=C(C(O)=C(C(=O)NCC(O)=O)C(=O)S2)C2=C1 QJFIWHWKGQQVNK-UHFFFAOYSA-N 0.000 claims description 2
- 206010054936 Cardiac cirrhosis Diseases 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- WURRDFYOJWNBQA-UHFFFAOYSA-N ClC1=CC=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=C1 Chemical compound ClC1=CC=C2SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=C1 WURRDFYOJWNBQA-UHFFFAOYSA-N 0.000 claims description 2
- TXBYAXHQTJYVEC-YFKPBYRVSA-N ClC1=CC=C2SC(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1 Chemical compound ClC1=CC=C2SC(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1 TXBYAXHQTJYVEC-YFKPBYRVSA-N 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims description 2
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims description 2
- 206010022657 Intestinal infarction Diseases 0.000 claims description 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- LQBPAHDTVYXJLR-UHFFFAOYSA-N OC1=C(C(=O)NCC(O)=O)C(=O)SC2=C1C=C(Cl)C=C2C Chemical compound OC1=C(C(=O)NCC(O)=O)C(=O)SC2=C1C=C(Cl)C=C2C LQBPAHDTVYXJLR-UHFFFAOYSA-N 0.000 claims description 2
- DTYZPHQDGFVXAU-UHFFFAOYSA-N OC1=C(C(=O)NCC(O)=O)C(=O)SC2=CC(C)=CC=C21 Chemical compound OC1=C(C(=O)NCC(O)=O)C(=O)SC2=CC(C)=CC=C21 DTYZPHQDGFVXAU-UHFFFAOYSA-N 0.000 claims description 2
- VWWZZNKIUJELAD-UHFFFAOYSA-N OC1=C(C(=O)NCC(O)=O)C(=O)SC2=CC(OC)=CC=C21 Chemical compound OC1=C(C(=O)NCC(O)=O)C(=O)SC2=CC(OC)=CC=C21 VWWZZNKIUJELAD-UHFFFAOYSA-N 0.000 claims description 2
- AXFQSABRLXZLES-UHFFFAOYSA-N OC1=C(C(=O)NCC(O)=O)C(=O)SC2=CC(OCCCC)=CC=C21 Chemical compound OC1=C(C(=O)NCC(O)=O)C(=O)SC2=CC(OCCCC)=CC=C21 AXFQSABRLXZLES-UHFFFAOYSA-N 0.000 claims description 2
- OBXPPDYDDCYLFS-UHFFFAOYSA-N OC1=C(C(SC=2C3=CC=CC=C3C=CC12)=O)C(=O)NCC(=O)O.OC1=C(C(SC2=C(C=CC=C12)C)=O)C(=O)NCC(=O)O Chemical compound OC1=C(C(SC=2C3=CC=CC=C3C=CC12)=O)C(=O)NCC(=O)O.OC1=C(C(SC2=C(C=CC=C12)C)=O)C(=O)NCC(=O)O OBXPPDYDDCYLFS-UHFFFAOYSA-N 0.000 claims description 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 2
- 206010063897 Renal ischaemia Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- QVSAZQNUYPHBOZ-UHFFFAOYSA-N S1C(=O)C(C(=O)NCC(O)=O)=C(O)C2=C1C=C(OC)C(OC)=C2 Chemical compound S1C(=O)C(C(=O)NCC(O)=O)=C(O)C2=C1C=C(OC)C(OC)=C2 QVSAZQNUYPHBOZ-UHFFFAOYSA-N 0.000 claims description 2
- YBPDIARQHBHDSS-UHFFFAOYSA-N S1C(=O)C(C(=O)NCC(O)=O)=C(O)C2=CC(OCCCCCC)=CC=C21 Chemical compound S1C(=O)C(C(=O)NCC(O)=O)=C(O)C2=CC(OCCCCCC)=CC=C21 YBPDIARQHBHDSS-UHFFFAOYSA-N 0.000 claims description 2
- YBZYPKGDBAFGFJ-UHFFFAOYSA-M [Na+].OC1=C(C(SC2=CC(=CC=C12)C=1C=NC=CC1)=O)C(=O)NCC(=O)[O-] Chemical compound [Na+].OC1=C(C(SC2=CC(=CC=C12)C=1C=NC=CC1)=O)C(=O)NCC(=O)[O-] YBZYPKGDBAFGFJ-UHFFFAOYSA-M 0.000 claims description 2
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 2
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 2
- 239000011790 ferrous sulphate Substances 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 102000044890 human EPO Human genes 0.000 claims description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 230000000451 tissue damage Effects 0.000 claims description 2
- 231100000827 tissue damage Toxicity 0.000 claims description 2
- 230000001052 transient effect Effects 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 238000002203 pretreatment Methods 0.000 claims 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 1
- PWCUPBBZKFTXMW-UHFFFAOYSA-N C=12SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC(Cl)=CC=1CC1=CC=CC=C1 Chemical compound C=12SC(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC(Cl)=CC=1CC1=CC=CC=C1 PWCUPBBZKFTXMW-UHFFFAOYSA-N 0.000 claims 1
- CFLDOIPLTBDWEW-UHFFFAOYSA-N CN1N=C(C(F)(F)F)C=C1C1=CC=CC2=C1SC(=O)C(C(=O)NCC(O)=O)=C2O Chemical compound CN1N=C(C(F)(F)F)C=C1C1=CC=CC2=C1SC(=O)C(C(=O)NCC(O)=O)=C2O CFLDOIPLTBDWEW-UHFFFAOYSA-N 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- MCHSAKXYMWRKLV-UHFFFAOYSA-N CN1N=C(C(F)(F)F)C=C1C1=CC(Cl)=CC2=C1SC(=O)C(C(=O)NCC(O)=O)=C2O Chemical compound CN1N=C(C(F)(F)F)C=C1C1=CC(Cl)=CC2=C1SC(=O)C(C(=O)NCC(O)=O)=C2O MCHSAKXYMWRKLV-UHFFFAOYSA-N 0.000 description 1
- MIWHUEWOMTYEJQ-UHFFFAOYSA-N COC1=CC=CC=C1C1=CC=C(SC(=O)C(C(=O)NCC(O)=O)=C2O)C2=C1 Chemical compound COC1=CC=CC=C1C1=CC=C(SC(=O)C(C(=O)NCC(O)=O)=C2O)C2=C1 MIWHUEWOMTYEJQ-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000894007 species Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11497108P | 2008-11-14 | 2008-11-14 | |
| US61/114,971 | 2008-11-14 | ||
| PCT/US2009/064065 WO2010056767A1 (en) | 2008-11-14 | 2009-11-11 | Thiochromene derivatives as hip hydroxylase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012508752A JP2012508752A (ja) | 2012-04-12 |
| JP2012508752A5 true JP2012508752A5 (https=) | 2012-12-27 |
| JP5649584B2 JP5649584B2 (ja) | 2015-01-07 |
Family
ID=41698287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011536447A Expired - Fee Related JP5649584B2 (ja) | 2008-11-14 | 2009-11-11 | Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8927591B2 (https=) |
| EP (1) | EP2370422B1 (https=) |
| JP (1) | JP5649584B2 (https=) |
| CN (2) | CN105037323A (https=) |
| AU (1) | AU2009314155B2 (https=) |
| IL (1) | IL212762A (https=) |
| NZ (1) | NZ592741A (https=) |
| WO (1) | WO2010056767A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8614204B2 (en) * | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| CA2528232C (en) | 2003-06-06 | 2010-05-25 | Fibrogen, Inc. | Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin |
| US8269008B2 (en) | 2007-12-03 | 2012-09-18 | Fibrogen, Inc. | Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions |
| EP2252619B1 (en) | 2008-01-11 | 2013-10-09 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
| US8324405B2 (en) | 2008-02-05 | 2012-12-04 | Fibrogen, Inc. | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors |
| EP2334682B1 (en) | 2008-08-20 | 2017-10-04 | Fibrogen, Inc. | Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators |
| WO2010056767A1 (en) | 2008-11-14 | 2010-05-20 | Fibrogen, Inc. | Thiochromene derivatives as hip hydroxylase inhibitors |
| CA2800498C (en) | 2010-03-31 | 2021-11-16 | The Scripps Research Institute | Reprogramming cells |
| EP2465841A1 (en) * | 2010-11-19 | 2012-06-20 | Lonza Ltd. | Preparation of esters of mono- or dicarboxylic non-aromatic and aromatic acids |
| CN103608346B (zh) | 2011-02-02 | 2016-06-15 | 菲布罗根有限公司 | 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物 |
| GB201102659D0 (en) | 2011-02-15 | 2011-03-30 | Isis Innovation | Assay |
| NO2686520T3 (https=) | 2011-06-06 | 2018-03-17 | ||
| GB201113101D0 (en) | 2011-07-28 | 2011-09-14 | Isis Innovation | Assay |
| AU2013229922B2 (en) | 2012-03-09 | 2017-09-28 | Kyntra Bio, Inc. | 4 -hydroxy- isoquinoline compounds as HIF hydroxylase inhibitors |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| EP2872487B1 (en) | 2012-07-16 | 2017-04-26 | Fibrogen, Inc. | Process for making isoquinoline compounds |
| KR20210130849A (ko) | 2012-07-16 | 2021-11-01 | 피브로겐, 인크. | 프롤릴 하이드록실라제 억제제 [(4-하이드록시-1-메틸-7-페녹시-아이소퀴놀린-3-카보닐)-아미노]-아세트산의 결정형 |
| KR20210104173A (ko) | 2013-06-06 | 2021-08-24 | 피브로겐, 인크. | Hif 하이드록실라제 억제자의 약학적 제형 |
| SG10201910773VA (en) | 2013-06-13 | 2020-01-30 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
| JP6506390B2 (ja) | 2014-09-02 | 2019-04-24 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． | キノリノン系化合物及びその薬物への使用 |
| AU2016209126A1 (en) | 2015-01-23 | 2017-08-10 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| US20180065933A1 (en) * | 2015-03-20 | 2018-03-08 | Akebia Therapeutics, Inc. | Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors |
| US11324734B2 (en) | 2015-04-01 | 2022-05-10 | Akebia Therapeutics, Inc. | Compositions and methods for treating anemia |
| CA3062972C (en) | 2017-05-09 | 2021-09-14 | Kind Pharmaceutical | Indolizine derivatives and their application in medicine |
| EP3790863A1 (en) | 2018-05-09 | 2021-03-17 | Akebia Therapeutics Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| WO2021216530A1 (en) | 2020-04-20 | 2021-10-28 | Akebia Therapeutics, Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| CN117999069A (zh) | 2021-05-27 | 2024-05-07 | 凯克斯生物制药公司 | 柠檬酸铁的儿科调配物 |
| CN115944626B (zh) * | 2022-12-08 | 2024-04-19 | 桂林医学院附属医院 | 小分子化合物在制备抗缺氧或缺血再灌注损伤药物中的应用 |
| CN121202828B (zh) * | 2025-11-27 | 2026-04-14 | 中节能万润股份有限公司 | 一种甲基丙烯酸酯类光刻胶树脂单体的制备方法 |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4036964A (en) | 1973-10-11 | 1977-07-19 | Beecham Group Limited | Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis |
| US3989704A (en) | 1973-10-30 | 1976-11-02 | Sandoz, Inc. | 3-Substituted-4-aryl isoquinolines |
| GB1582217A (en) | 1978-02-27 | 1981-01-07 | Teijin Ltd | Penicillin derivatives medicines containing the same and process for producing the same |
| DE2818423A1 (de) | 1978-04-27 | 1979-11-08 | Hoechst Ag | Neue isochinolinderivate und verfahren zu ihrer herstellung |
| DE3233424A1 (de) | 1982-09-09 | 1984-03-15 | Hoechst Ag, 6230 Frankfurt | Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
| US4559403A (en) | 1983-05-19 | 1985-12-17 | Hoffmann-La Roche Inc. | Substituted isoquinolines |
| FR2562893B1 (fr) * | 1984-04-12 | 1986-06-27 | Lipha | Derives de l'hydroxy-4-2h-1-benzothiopyran-2-one, leurs preparations et applications dans le domaine rodenticide |
| US4584379A (en) | 1985-01-22 | 1986-04-22 | Merrell Dow Pharmaceuticals Inc. | Isoquinoline thromboxane synthetase inhibitors |
| US4822800A (en) | 1986-06-09 | 1989-04-18 | Ortho Pharmaceutical Corporation | Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties |
| GB8816519D0 (en) | 1987-07-23 | 1988-08-17 | Ici Plc | Antibiotic compounds |
| US4966906A (en) | 1987-11-27 | 1990-10-30 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-isoquinolinecarboxamides |
| US4952588A (en) | 1987-11-27 | 1990-08-28 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides |
| EP0532466A3 (en) | 1991-09-12 | 1993-06-16 | Ciba-Geigy Ag | Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use |
| US5378720A (en) | 1991-12-19 | 1995-01-03 | Sterling Winthrop Inc. | Saccharin derivative proteolytic enzyme inhibitors |
| EP0626178A1 (de) | 1993-05-17 | 1994-11-30 | Ciba-Geigy Ag | Verwendung von Hemmstoffen von HIV-Aspartatproteasen zur Bekämpfung von Tumorerkrankungen |
| EP0650961B1 (de) | 1993-11-02 | 1997-03-05 | Hoechst Aktiengesellschaft | Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| ES2101420T3 (es) | 1993-11-02 | 1997-07-01 | Hoechst Ag | Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos. |
| NZ270267A (en) | 1993-12-30 | 1997-03-24 | Hoechst Ag | 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions |
| US5563143A (en) | 1994-09-21 | 1996-10-08 | Pfizer Inc. | Catechol diether compounds as inhibitors of TNF release |
| AU4515696A (en) | 1994-12-12 | 1996-07-03 | Merck & Co., Inc. | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase |
| US5741657A (en) | 1995-03-20 | 1998-04-21 | The Regents Of The University Of California | Fluorogenic substrates for β-lactamase and methods of use |
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| US5955604A (en) | 1996-10-15 | 1999-09-21 | The Regents Of The University Of California | Substrates for β-lactamase and uses thereof |
| WO1998023608A1 (en) | 1996-11-27 | 1998-06-04 | Dupont Pharmaceuticals Company | Novel integrin receptor antagonists |
| JP4074683B2 (ja) * | 1997-03-31 | 2008-04-09 | 富士フイルム株式会社 | ベンゾピラン化合物の製造方法 |
| AU7526798A (en) | 1997-04-18 | 1998-11-27 | Smithkline Beecham Plc | Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders |
| GB9707830D0 (en) | 1997-04-18 | 1997-06-04 | Smithkline Beecham Plc | Novel compounds |
| DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| FR2779963A1 (fr) | 1998-06-22 | 1999-12-24 | Centre Nat Rech Scient | Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer |
| IT1302677B1 (it) | 1998-10-15 | 2000-09-29 | Zambon Spa | Derivati benzazinici inibitori della fosfodiesterasi 4 |
| WO2000064877A1 (en) | 1999-04-26 | 2000-11-02 | Neurogen Corporation | 2-aminoquinolinecarboxamides: neurokinin receptor ligands |
| IT1320162B1 (it) | 2000-02-09 | 2003-11-18 | Rotta Research Lab | Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico. |
| US7622503B2 (en) | 2000-08-24 | 2009-11-24 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
| FI20002044A0 (fi) | 2000-09-15 | 2000-09-15 | Orion Yhtymae Oyj | Comt-entsyymiä estäviä naftaleenijohdannaisia |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| JP4590157B2 (ja) | 2001-03-21 | 2010-12-01 | アイシス イノヴェイション リミテッド | アッセイ、方法および手段 |
| US6716866B2 (en) | 2001-06-13 | 2004-04-06 | Genesoft Pharmaceuticals, Inc. | Aryl-benzimidazole compounds having antiinfective activity |
| US6777425B2 (en) | 2001-06-13 | 2004-08-17 | Genesoft Pharmaceuticals, Inc. | Isoquinoline compounds having antiinfective activity |
| CA2448737C (en) | 2001-07-20 | 2010-06-01 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| US7294457B2 (en) | 2001-08-07 | 2007-11-13 | Boehringer Ingelheim (Canada) Ltd. | Direct binding assay for identifying inhibitors of HCV polymerase |
| US6762318B2 (en) | 2001-12-03 | 2004-07-13 | Novo Nordisk A/S | Glucagon antagonists |
| CN102552263A (zh) | 2001-12-06 | 2012-07-11 | 法布罗根股份有限公司 | 提高内源性红细胞生成素(epo)的方法 |
| GB0206711D0 (en) | 2002-03-21 | 2002-05-01 | Isis Innovation | HIF Inhibitor |
| CN1506359A (zh) | 2002-12-05 | 2004-06-23 | �й�ҽѧ��ѧԺҩ���о��� | 新的香豆素酰胺衍生物及其制法和其药物组合物与用途 |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| CA2528232C (en) | 2003-06-06 | 2010-05-25 | Fibrogen, Inc. | Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin |
| WO2005007192A2 (en) | 2003-06-06 | 2005-01-27 | Fibrogen, Inc. | Cytoprotection through the use of hif hydroxylase inhibitors |
| CN100418948C (zh) | 2003-07-15 | 2008-09-17 | 麦克公司 | 羟基吡啶cgrp受体抗拮抗剂 |
| WO2005011696A1 (en) | 2003-08-01 | 2005-02-10 | Fibrogen, Inc. | Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers |
| WO2005014533A2 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| US7304168B2 (en) | 2003-08-14 | 2007-12-04 | Board Of Regents, University Of Texas System | Photo-caged fluorescent molecules |
| KR20070004676A (ko) | 2004-02-10 | 2007-01-09 | 얀센 파마슈티카 엔.브이. | 알파４ 인테그린의 길항제로서의 피리다지논 |
| KR20070041720A (ko) | 2004-07-15 | 2007-04-19 | 파워프리사이스 솔루션즈, 인코포레이티드 | 1 회 작동 상태 검출 방법 및 장치 |
| EP1676834A1 (en) | 2004-12-30 | 2006-07-05 | Sanofi-Aventis Deutschland GmbH | Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation |
| WO2006094292A2 (en) | 2005-03-02 | 2006-09-08 | Fibrogen, Inc. | Thienopyridine compounds, and methods of use thereof |
| US20060276477A1 (en) | 2005-06-06 | 2006-12-07 | Fibrogen, Inc. | Treatment method for anemia |
| AU2006259352A1 (en) | 2005-06-15 | 2006-12-28 | Fibrogen, Inc. | Use of HIF 1alfa modulators for treatment of cancer |
| JP2009506068A (ja) | 2005-08-25 | 2009-02-12 | エモリー・ユニバーシティ | Ｈｉｆ阻害剤 |
| WO2007038571A2 (en) * | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| HUE056836T2 (hu) | 2005-12-01 | 2022-03-28 | Nuevolution As | Enzimatikus kódolási eljárások nagy könyvtárak hatékony szintéziséhez |
| JP5202327B2 (ja) | 2005-12-09 | 2013-06-05 | アムジエン・インコーポレーテツド | プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用 |
| EP2476669A1 (en) | 2006-01-27 | 2012-07-18 | Fibrogen, Inc. | Cyanoisoquinoline compounds and methods of use thereof |
| AR059733A1 (es) * | 2006-03-07 | 2008-04-23 | Smithkline Beecham Corp | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
| CN103497184A (zh) * | 2006-04-04 | 2014-01-08 | 菲布罗根有限公司 | 作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物 |
| WO2007136990A2 (en) | 2006-05-16 | 2007-11-29 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| US7713986B2 (en) | 2006-06-15 | 2010-05-11 | Fibrogen, Inc. | Compounds and methods for treatment of chemotherapy-induced anemia |
| US20070293575A1 (en) | 2006-06-15 | 2007-12-20 | Fibrogen, Inc. | Compounds and methods for treatment of cancer-related anemia |
| JO2934B1 (en) | 2006-06-23 | 2015-09-15 | سميث كلاين بيتشام كوربوريشن | Prolyl hydroxylase inhibitors |
| US8048892B2 (en) | 2006-12-18 | 2011-11-01 | Amgen Inc. | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| EP2111399A2 (en) | 2006-12-18 | 2009-10-28 | Amgen Inc. | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| CL2008000065A1 (es) | 2007-01-12 | 2008-09-22 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia. |
| TW200845991A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: hydroxylase inhibitors |
| CA2683758A1 (en) * | 2007-04-18 | 2008-10-30 | Merck & Co., Inc. | Novel 1,8-naphthyridine compounds |
| EP2142509B1 (en) | 2007-04-18 | 2013-12-04 | Amgen, Inc | Quinolones and azaquinolones that inhibit prolyl hydroxylase |
| EP2155680B1 (en) | 2007-04-18 | 2013-12-04 | Amgen, Inc | Indanone derivatives that inhibit prolyl hydroxylase |
| US8097620B2 (en) | 2007-05-04 | 2012-01-17 | Amgen Inc. | Diazaquinolones that inhibit prolyl hydroxylase activity |
| ES2389063T3 (es) | 2007-05-04 | 2012-10-22 | Amgen, Inc | Derivados de tienopiridina y tiazolopiridina que inhiben la actividad prolil hidroxilasa |
| WO2009039321A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039322A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039323A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| US20100305133A1 (en) | 2007-11-30 | 2010-12-02 | Smithkline Beecham Corporation | Prolyl Hydroxylase Inhibitors |
| WO2009070644A1 (en) | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| US8269008B2 (en) | 2007-12-03 | 2012-09-18 | Fibrogen, Inc. | Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions |
| WO2009075826A1 (en) * | 2007-12-07 | 2009-06-18 | Fibrogen, Inc. | Methods for increasing white blood cells |
| EP2227232A1 (en) | 2007-12-07 | 2010-09-15 | Fibrogen, Inc. | Methods for inhibiting t helper cell differentiation |
| WO2009086044A1 (en) | 2007-12-19 | 2009-07-09 | Smith Kline Beecham Corporation | Prolyl hydroxylase inhibitors |
| EP2252619B1 (en) | 2008-01-11 | 2013-10-09 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
| US8324405B2 (en) | 2008-02-05 | 2012-12-04 | Fibrogen, Inc. | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors |
| EP2334682B1 (en) | 2008-08-20 | 2017-10-04 | Fibrogen, Inc. | Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators |
| WO2010056767A1 (en) | 2008-11-14 | 2010-05-20 | Fibrogen, Inc. | Thiochromene derivatives as hip hydroxylase inhibitors |
| CN103608346B (zh) | 2011-02-02 | 2016-06-15 | 菲布罗根有限公司 | 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物 |
| AU2013229922B2 (en) | 2012-03-09 | 2017-09-28 | Kyntra Bio, Inc. | 4 -hydroxy- isoquinoline compounds as HIF hydroxylase inhibitors |
| EP2872487B1 (en) | 2012-07-16 | 2017-04-26 | Fibrogen, Inc. | Process for making isoquinoline compounds |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| KR20210130849A (ko) | 2012-07-16 | 2021-11-01 | 피브로겐, 인크. | 프롤릴 하이드록실라제 억제제 [(4-하이드록시-1-메틸-7-페녹시-아이소퀴놀린-3-카보닐)-아미노]-아세트산의 결정형 |
| CA2899024C (en) | 2013-01-24 | 2022-01-04 | Fibrogen, Inc. | Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid |
| KR20210104173A (ko) | 2013-06-06 | 2021-08-24 | 피브로겐, 인크. | Hif 하이드록실라제 억제자의 약학적 제형 |
-
2009
- 2009-11-11 WO PCT/US2009/064065 patent/WO2010056767A1/en not_active Ceased
- 2009-11-11 CN CN201510259787.8A patent/CN105037323A/zh active Pending
- 2009-11-11 AU AU2009314155A patent/AU2009314155B2/en not_active Ceased
- 2009-11-11 EP EP09756097.3A patent/EP2370422B1/en active Active
- 2009-11-11 CN CN200980154106.4A patent/CN102272117B/zh not_active Expired - Fee Related
- 2009-11-11 JP JP2011536447A patent/JP5649584B2/ja not_active Expired - Fee Related
- 2009-11-11 US US13/128,620 patent/US8927591B2/en active Active
- 2009-11-11 NZ NZ592741A patent/NZ592741A/xx not_active IP Right Cessation
-
2011
- 2011-05-08 IL IL212762A patent/IL212762A/en active IP Right Grant
-
2014
- 2014-12-24 US US14/582,914 patent/US9149476B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012508752A5 (https=) | ||
| JP7602272B2 (ja) | Ｋｒａｓ関連がんを治療する方法 | |
| RU2008134664A (ru) | Цианоизохинолиновые соединения (варианты), фармацевтическая композиция на их основе, способ ингибирования активности гидроксилазы гипоксия-индуцибельного фактора (hif) и способ лечения и/или профилактики состояния, связанного с hif и/или состояния, связанного с эритропоэтином и/или анемии | |
| JP2015522616A5 (https=) | ||
| AU2015231275B2 (en) | Antifungal compound process | |
| AU2015231270B2 (en) | Antifungal compound process | |
| JP5747142B2 (ja) | Ｄｙｒｋを阻害する化合物を含有する医薬組成物 | |
| JP2008535790A5 (https=) | ||
| CA2647596A1 (en) | Pyrrolo- and thiazolo-pyridine compounds as hif modulators | |
| JP2014530240A5 (https=) | ||
| JP2014532070A5 (https=) | ||
| JP2012532112A5 (https=) | ||
| AU2016323782A1 (en) | Antifungal compound process | |
| EP3119755A1 (en) | Antifungal compound process | |
| JP2018514524A (ja) | ５−芳香族アルキニル基置換ベンズアミド系化合物並びにその製造方法、薬物組成物及び使用 | |
| EP3271347A1 (en) | Antifungal compounds and processes for making | |
| JP7794910B2 (ja) | Ｅａａｔ２活性化因子およびその使用方法 | |
| CN105120867A (zh) | 用于治疗纤维化疾病的化合物 | |
| CA2978627A1 (en) | Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance | |
| EP3119746A1 (en) | Antifungal compound process | |
| WO2022010948A1 (en) | Novel cell metabolism modulating compounds and uses thereof for the treatment of viral diseases | |
| BR112014008412A2 (pt) | derivados de pirimidin-4-ona e sua utilização no tratamento, na melhora ou na prevenção de uma doença viral | |
| EP3442948A1 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| AU2011256989B2 (en) | 8-hydroxy-quinoline derivatives | |
| JP2008519815A5 (https=) |